Newly Diagnosed Glioblastoma | Norton Healthcare

Indication: Newly Diagnosed Glioblastoma

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Sub-indication: CNS Cancer

Study Type: Drug Study

Principal Investigator: Renato LaRocca, M.D.
Norton Brain Tumor Center

Sponsor: Sponsor: MimiVax, LLC

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.